SANGAMO THERAPEUTICS, INC (SGMO) Form 8-K — Sep 8, 2026
Sangamo Therapeutics completed the sale of substantially all of its assets to Eli Lilly on September 4, 2026, for $50 million in cash plus the assumption of certain specified liabilities. The transferred Lilly Assets include the AAV capsid engineering platform with the proprietary STAC-BBB capsid, the zinc finger protein technology platform, the Modular Integrase genome editing platform, the ST-506 prion disease program, related intellectual property, and rights to future milestone and royalty payments. The sale closed through a court-supervised auction under Sangamo's Chapter 11 case (Case No.
Key figures
- Revenue
- 720000
- Net Income
- -11165298
- Total Debt
- 97132393
- Debt Amount
- 18000000
- Total Assets
- 155117944
- Cash Position
- 16906955
- Deal Value Usd
- 50000000
- Dip draw
- $18,000,000 incurred under Replacement DIP Facility (Future Solutions Investments LLC, 7/24/2026)
- Mor period
- July 1-31, 2026
- July receipts
- 18058990
- Bankruptcy case
- No. 26-10989 (Bankr. D. Del.), petition filed June 23, 2026
- Initial dip draw
- 10500000
- Postpetition debt
- 19038048
- July disbursements
- 15534279
- Cumulative net loss
- -14920356
- Full time employees
- 73
- Initial dip repayment
- 11432958
- Ending equity net worth
- 57985551
- Prepetition priority debt
- 32543
- Reorganization items july
- 4244225
- Prepetition unsecured debt
- 78061802
- Balance sheet total liabilities incl intercompany
- 147383000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.